CanRIO Member Publications

Immune Checkpoint Inhibitors in Cancer Immunotherapy

Posted June 1, 2021
CMAJ 2020 Immune checkpoint inhibitors (ICI’s) are increasingly used in cancer immunotherapy, and have shown unprecedented survival benefit in a number of malignancies with historically… Read More

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Posted February 23, 2021
Ann Rheum Dis 2020 Background: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given… Read More

Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology

Posted January 21, 2021

Cancer Immunol Immunother 2021
Limited data are available on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with preexisting autoimmune diseases… Read More

Moving towards personalized treatments of immune-related adverse events

Posted January 20, 2021

Nat Rev Clin Oncol 2020
The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour… Read More

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy

Posted January 20, 2021

N Engl J Med 2020
A case description of the successful use of tofacitinib in a patient with gastric cancer receiving pembrolizumab whose… Read More

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients

Posted January 20, 2021

Sci Rep 2020
The ‘real-world’ patient population of metastatic melanoma is not fully represented in clinical trials investigating checkpoint inhibitors. We described therapy discontinuation… Read More

Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort

Posted January 20, 2021

Autoimmun Rev 2020
Objective: Although immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, their use is associated with immune toxicities referred to as immune-related… Read More

Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist

Posted January 19, 2021

J Rheum 2019
Immune checkpoint inhibitors have revolutionized cancer therapy by blocking inhibitory pathways of the immune system to fight cancer cells. Their use… Read More

Adverse events associated with immune checkpoint inhibitor treatment for cancer

Posted January 19, 2021

CMAJ 2019
Inhibitors against cytotoxic T-lymphocyte--associated protein 4 and programmed cell death 1 immune checkpoints are novel agents that modulate immune pathways and enhance… Read More

Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis

Posted January 19, 2021

Clin Rheumatol 2019
Immunotherapy for cancer treatment continues to evolve, and immune checkpoints have proven successful therapeutic targets. With success has come the challenge… Read More